Helus Pharma, operating as Cybin, is trading 10.69% up at $11.17 as investors anticipate CEO Michael Halstead's fireside chat today, August 12, 2026. Halstead is scheduled to speak at 12:00 p.m. EDT at the Canaccord Genuity 46th Annual Growth Conference, where the company is expected to provide updates on its clinical development and strategic direction. The company continues to advance its HLP003 clinical program, with topline data from the Phase 3 APPROACH study expected in Q4 2026.